Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Stuttgart - Delayed Quote • EUR Medivir AB (MVR0.SG) Follow Compare 0.1570 -0.0005 (-0.32%) As of 8:09:49 AM GMT+1. Market Open. Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for MVR0.SG 1D 5D -5.14% 1M -30.53% 3M -31.14% 6M -39.62% YTD -32.03% 1Y -40.42% 5Y -85.68% All -97.79% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: MVR0.SG View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Medivir AB (FRA:MVR0) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges 3 Penny Stocks With Market Caps Larger Than US$10M To Watch Medivir to present at the Pareto Securities Healthcare Conference Medivir's fostrox + Lenvima confirm promise of improved outcomes in advanced liver cancer, detailed and mature data presented at ESMO Medivir to present mature clinical data for fostrox + Lenvima at ESMO Conference and to host a webcast on September 16 Medivir to present updated clinical data for fostrox + Lenvima in HCC at ESMO Conference in September Number of shares and votes in Medivir AB on 28 June 2024 Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2024 Medivir to present at Redeye Growth Day Related Tickers MVR0.F Medivir AB (publ) 0.1315 0.00% MVIR.ST Medivir AB (publ) 1.9100 0.00% ARMP Armata Pharmaceuticals, Inc. 2.0872 -2.48% ACOGF CFRX ContraFect Corporation SPRO Spero Therapeutics, Inc. 0.7817 -1.60% NRIX Nurix Therapeutics, Inc. 15.90 -6.83% SLNO Soleno Therapeutics, Inc. 46.09 +2.20%